Response of Human Pancreatic Cancer Cell Xenografts to Tetraiodothyroacetic Acid Nanoparticles

Hormones and Cancer

Volumn 4, Issue 3, 2013, Pages 176-185

  Yalcin, Murat ^a,b   Lin, Hung Yun ^c   Sudha, Thangirala ^a   Bharali, Dhruba J ^a   Meng, Ran ^a   Tang, Heng Yuan ^a   Davis, Faith B ^d   Stain, Steven C ^d   Davis, Paul J ^a,d   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ULUDAG UNIVERSITY   (Turkey)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; NANOPARTICLE; PROTEIN BCL X; PROTEIN P21; PROTEIN P53; TETRAIODOTHYROACETIC ACID NANOPARTICLE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANGIOGENESIS; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; THYROXINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84877029051     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-013-0137-y     Document Type: Article

References (54)

1. Philip PA et al (2009) Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 27: 5660-5669.
2. Oettle H, Neuhaus P (2007) Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs 67: 2293-2310.
3. Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D (2009) Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 27: 2269-2277.
4. Stathis A, Moore MJ (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7: 163-172.
5. Mackenzie RP, McCollum AD (2009) Novel agents for the treatment of adenocarcinoma of the pancreas. Expert Rev Anticancer Ther 9: 1473-1485.
6. Mahalingam D, Giles F (2008) Challenges in developing targeted therapy for pancreatic adenocarcinoma. Expert Opin Ther Targets 12: 1389-1401.
7. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prevost N, Tarin D, Shattil SJ, Cheresh DA (2009) An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 15: 1163-1169.
8. Cai W, Chen X (2006) Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 6: 407-428.
9. Belmadani S, Zerfaoui M, Boulares HA, Palen DI, Matrougui K (2008) Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, alphavbeta3-integrin, and TGF-beta1 in response to ANG II and high glucose. Am J Physiol Heart Circ Physiol 295: H69-76.
10. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22.
11. Hsu AR, Veeravagu A, Cai W, Hou LC, Tse V, Chen X (2007) Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment. Recent Pat Anticancer Drug Discov 2: 143-158.
12. Kumar CC (2003) Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 4: 123-131.
13. Nakamura I, le Duong T, Rodan SB, Rodan GA (2007) Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab 25: 337-344.
14. Mousa SS, Davis FB, Davis PJ, Mousa SA (2010) Human platelet aggregation and degranulation is induced in vitro by L-thyroxine, but not by 3, 5, 3'-triiodo-L-thyronine or diiodothyropropionic acid (DITPA). Clin Appl Thromb Hemost 16: 288-293.
15. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S, Davis PJ (2005) Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146: 2864-2871.
16. Lin HY, Tang HY, Shih A, Keating T, Cao G, Davis PJ, Davis FB (2007) Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids 72: 180-187.
17. Lin HY, Tang HY, Keating T, Wu YH, Shih A, Hammond D, Sun M, Hercbergs A, Davis FB, Davis PJ (2008) Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated. Carcinogenesis 29: 62-69.
18. Davis PJ, Davis FB, Lin HY, Mousa SA, Zhou M, Luidens MK (2009) Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am J Physiol Endocrinol Metab 297: E1238-1246.
19. Davis FB, Mousa SA, O'Connor L, Mohamed S, Lin HY, Cao HJ, Davis PJ (2004) Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 94: 1500-1506.
20. Mousa SA, O'Connor L, Davis FB, Davis PJ (2006) Proangiogenesis action of the thyroid hormone analog 3, 5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology 147: 1602-1607.
21. Luidens MK, Mousa SA, Davis FB, Lin HY, Davis PJ (2010) Thyroid hormone and angiogenesis. Vascul Pharmacol 52: 142-145.
22. Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA, Incerpi S, Drusano GL, Davis FB, Davis PJ (2009) L-Thyroxine vs. 3, 5, 3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 296: C980-991.
23. Tang HY, Lin HY, Zhang S, Davis FB, Davis PJ (2004) Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 145: 3265-3272.
24. Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, Yalcin M, Aljada A, Dyskin E, Davis FB, Lin HY, Davis PJ (2008) Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 11: 183-190.
25. Glinskii AB, Glinsky GV, Lin HY, Tang HY, Sun M, Davis FB, Luidens MK, Mousa SA, Hercbergs AH, Davis PJ (2009) Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 8: 3554-3562.
26. Moreno M, de Lange P, Lombardi A, Silvestri E, Lanni A, Goglia F (2008) Metabolic effects of thyroid hormone derivatives. Thyroid 18: 239-253.
27. Yalcin M, Dyskin E, Lansing L, Bharali DJ, Mousa SS, Bridoux A, Hercbergs AH, Lin HY, Davis FB, Glinsky GV, Glinskii A, Ma J, Davis PJ, Mousa SA (2010) Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 95: 1972-1980.
28. Yalcin M, Bharali DJ, Lansing L, Dyskin E, Mousa SS, Hercbergs A, Davis FB, Davis PJ, Mousa SA (2009) Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res 29: 3825-3831.
29. Lin HY, Landersdorfer CB, London D, Meng R, Lim CU, Lin C, Lin S, Tang HY, Brown D, van Scoy B, Kulawy R, Queimado L, Drusano GL, Louie A, Davis FB, Mousa SA, Davis PJ (2011) Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system. PLoS Comput Biol 7: e1001073.
30. Davis PJ, Shih A, Lin HY, Martino LJ, Davis FB (2000) Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. J Biol Chem 275: 38032-38039.
31. Lin HY, Lansing L, Merillon JM, Davis FB, Tang HY, Shih A, Vitrac X, Krisa S, Keating T, Cao HJ, Bergh J, Quackenbush S, Davis PJ (2006) Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB J 20: 1742-1744.
32. Zhang S, Cao HJ, Davis FB, Tang HY, Davis PJ, Lin HY (2004) Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br J Cancer 91: 178-185.
33. Shih A, Davis FB, Lin HY, Davis PJ (2002) Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK- and p53-dependent mechanism. J Clin Endocrinol Metab 87: 1223-1232.
34. Davis FB, Tang HY, Shih A, Keating T, Lansing L, Hercbergs A, Fenstermaker RA, Mousa A, Mousa SA, Davis PJ, Lin HY (2006) Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res 66: 7270-7275.
35. Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA (2008) Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis 11: 269-276.
36. Mousa SA, O'Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ (2005) The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol 46: 356-360.
37. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N (2008) The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214: 559-567.
38. Shih A, Zhang S, Cao HJ, Tang HY, Davis FB, Davis PJ, Lin HY (2004) Disparate effects of thyroid hormone on actions of epidermal growth factor and transforming growth factor-alpha are mediated by 3', 5'-cyclic adenosine 5'-monophosphate-dependent protein kinase II. Endocrinology 145: 1708-1717.
39. Lin HY, Shih A, Davis FB, Davis PJ (1999) Thyroid hormone promotes the phosphorylation of STAT3 and potentiates the action of epidermal growth factor in cultured cells. Biochem J 338(Pt 2): 427-432.
40. Ko AH, Youssoufian H, Gurtier J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballai S, Rowinsky EK (2012) A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic carcinoma. Invest New Drugs 30: 1597-1606.
41. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28: 3617-3622.
42. Yan CQ, Zhao YP (2009) Expression of angiogenic factors in pancreatic carcinoma cells and their significance. Zhonghua Wai Ke Za Zhi 47: 787-890.
43. Lee DY, Li YS, Chang SF, Zhou J, Ho HM, Chiu JJ, Chien S (2010) Oscillatory flow-induced proliferation of osteoblast-like cells is mediated by alphavbeta3 and beta1 integrins through synergistic interactions of focal adhesion kinase and Shc with phosphatidylinositol 3-kinase and the Akt/mTOR/p70S6K pathway. J Biol Chem 285: 30-42.
44. Chen YJ, Wei YY, Chen HT, Fong YC, Hsu CJ, Tsai CH, Hsu HC, Liu SH, Tang CH (2009) Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Physiol 221: 98-108.
45. Lossner D, Abou-Ajram C, Benge A, Aumercier M, Schmitt M, Reuning U (2009) Integrin alphavbeta3 upregulates integrin-linked kinase expression in human ovarian cancer cells via enhancement of ILK gene transcription. J Cell Physiol 220: 367-375.
46. Mangale SS, Modi DN, Reddy KV (2008) Identification of genes regulated by an interaction between alphavbeta3 integrin and vitronectin in murine decidua. Reprod Fertil Dev 20: 311-319.
47. Brady CA, Attardi LD (2010) p53 at a glance. J Cell Sci 123: 2527-2532.
48. Oliveira-Cunha M, Hadfield KD, Siriwardena AK, Newman W (2012) EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer. Pancreas 41: 428-434.
49. Le A, Rajeshkumar NV, Maitra A, Dang CV (2012) Conceptual framework for cutting the pancreatic cancer fuel supply. Clin Cancer Res 18: 4285-4290.
50. Lin H, Chen C, Li X, Chen BD (2002) Activation of the MEK/MAPK pathway is involved in bryostatin1-induced monocytic differenciation and up-regulation of X-linked inhibitor of apoptosis protein. Exp Cell Res 272: 192-198.
51. Cheng SY, Leonard JL, Davis PJ (2010) Molecular aspects of thyroid hormone actions. Endocr Rev 31: 139-170.
52. Davis PJ, Davis FB, Mousa SA, Luidens MK, Lin HY (2011) Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol 51: 99-115.
53. d'Angelo I et al (2010) Nanoparticles based on PLGA: Poloxmer blends for the delivery of proangiogenic growth factors. Mol Pharm 7: 1724-1733.
54. Kohl Y, Kaiser C, Bost W, Stracke F, Fournelle M, Wischke C, Thielecke H, Lendlein A, Kratz K, Lemor R (2011) Preparation and biological evaluation of multifunctional PLGA-nanoparticles designed for photoacoustic imaging. Nanomedicine 7: 228-237.